Atherosclerosis
Volume 205, Issue 2 , Pages 360-362 , August 2009

Effects of oxygen therapy on systemic inflammation and myeloperoxidase modified LDL in hypoxemic COPD patients

  • K. Zouaoui Boudjeltia

      Affiliations

    • Experimental Medicine Laboratory, ULB (Unit 222) ISPPC CHU Charleroi, Hôpital A. Vésale, Montigny-le-Tilleul, Belgium
    • ,
  • G. Tragas

      Affiliations

    • Service de Pneumologie, ISPPC CHU Charleroi, Hôpital A. Vésale, Montigny-le-Tilleul, Belgium
    • ,
  • S. Babar

      Affiliations

    • Experimental Medicine Laboratory, ULB (Unit 222) ISPPC CHU Charleroi, Hôpital A. Vésale, Montigny-le-Tilleul, Belgium
    • ,
  • A. Moscariello

      Affiliations

    • Service de Pneumologie, ISPPC CHU Charleroi, Hôpital A. Vésale, Montigny-le-Tilleul, Belgium
    • ,
  • V. Nuyens

      Affiliations

    • Experimental Medicine Laboratory, ULB (Unit 222) ISPPC CHU Charleroi, Hôpital A. Vésale, Montigny-le-Tilleul, Belgium
    • ,
  • P. Van Antwerpen

      Affiliations

    • Laboratory of Pharmaceutical Chemistry, ULB, Brussels, Belgium
    • ,
  • O. Gilbert

      Affiliations

    • Service de Pneumologie, ISPPC CHU Charleroi, Hôpital A. Vésale, Montigny-le-Tilleul, Belgium
    • ,
  • J. Ducobu

      Affiliations

    • Experimental Medicine Laboratory, ULB (Unit 222) ISPPC CHU Charleroi, Hôpital A. Vésale, Montigny-le-Tilleul, Belgium
    • ,
  • D. Brohee

      Affiliations

    • Experimental Medicine Laboratory, ULB (Unit 222) ISPPC CHU Charleroi, Hôpital A. Vésale, Montigny-le-Tilleul, Belgium
    • ,
  • M. Vanhaeverbeek

      Affiliations

    • Experimental Medicine Laboratory, ULB (Unit 222) ISPPC CHU Charleroi, Hôpital A. Vésale, Montigny-le-Tilleul, Belgium
    • ,
  • A. Van Meerhaeghe

      Affiliations

    • Service de Pneumologie, ISPPC CHU Charleroi, Hôpital A. Vésale, Montigny-le-Tilleul, Belgium
    • Corresponding Author InformationCorresponding author at: CHU Charleroi, Hôpital André Vésale, 706 route de Gozée, Montigny-le-Tilleul 6110, Belgium. Tel.: +32 71921511; fax: +32 71922568.

Received 26 November 2008

References 

  1. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107:1514–1519
  2. Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax. 2003;58:388–393
  3. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA. TORCH Clinical Endpoint Committee Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax. 2007;62:411–415
  4. Takabatake N, Nakamura H, Abe S, et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-α system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1179–1184
  5. Kim KS, Rajagopal V, Gonsalves C, Johnson C, Karla VK. A novel role of hypoxia-inducible factor in cobalt chloride- and hypoxia-mediated expression of IL-8 chemokine in human endothelial cells. J Immunol. 2006;177:7211–7224
  6. Moguilevsky N, Zouaoui Boudjeltia K, Babar S, et al. Monoclonal antibodies against LDL progressively oxidized by myeloperoxidase react with ApoB-100 protein moiety and human atherosclerotic lesions. Biochem Biophys Res Commun. 2004;323:1223–1228
  7. Bratel T, Wennlund A, Carlström K. Impact of hypoxaemia on neuroendocrine function and catecholamine secretion in chronic obstructive pulmonary disease (COPD). Effects of long-term oxygen treatment. Respir Med. 2000;94:1221–1228
  8. Zouaoui Boudjeltia K, Moguilevsky N, Legssyer I, et al. Oxidation of low-density lipoproteins by myeloperoxidase at the surface of endothelial cells: an additional mechanism to subendothelium oxidation. Biochem Biophys Res Commun. 2004;325:434–438
  9. Bleeke T, Zhang H, Madamanchi N, Patterson C, Faber JE. Catecholamine-induced vascular wall growth is dependent on generation of reactive oxygen species. Circ Res. 2004;94:37–45
  10. Griendling KK, Sorescu D, Ushio-Fukai M. NAD (P) H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86:494–501
  11. Marquez LA, Dunford HB, Van War H. Kinetic studies on the reaction of compound II of myeloperoxidase with ascorbic acid. Role of ascorbic acid in myeloperoxidase function. J Biol Chem. 1990;265:5666–5670
  12. Heinecke JW. Oxidative stress: new approaches to diagnosis and prognosis in atherosclerosis. Am J Cardiol. 2003;91:12A–16A
  13. Buffon A, Biasucci LM, Liuzzo G, D’Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med. 2002;347:5–12
  14. Agusti A. Thomas a Neff lecture. Chronic obstructive pulmonary disease: a systemic disease. Proc Am Thorac Soc. 2006;3:478–481
  15. Zouaoui Boudjeltia K, Legssyer I, Van Antwerpen P, et al. Triggering of inflammatory response by myeloperoxidase-oxidized LDL. Biochem Cell Biol. 2006;84:805–812
  16. Inoue T, Komoda H, Nonaka M, Kameda M, Uchida T, Node K. Interleukin-8 as an independent predictor of long-term clinical outcome in patients with coronary artery disease. Int J Cardiol. 2008;124:319–325

PII: S0021-9150(09)00075-6

doi: 10.1016/j.atherosclerosis.2009.01.028

Atherosclerosis
Volume 205, Issue 2 , Pages 360-362 , August 2009

Article Tools